Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Benzinga · 3d ago
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.